S339
Clinical - Breast
ESTRO 2026
Keywords: preoperative, chemoradiation, unfavourable subtypes
the symptom domain score was significantly increased at 14 days post-RT (p < 0.01), and no domain showed a significant change at 90 days post-RT compared with baseline. Conclusion: Most skin symptoms worsened at 14 days after RT compared to baseline; however, the majority had returned to baseline by 90 days post-RT. Some symptoms, such as discomfort and pain, showed improvements exceeding baseline levels. Given the single-arm design, the incremental HRQoL benefit attributable to StrataXRT remains uncertain and warrants randomized evaluation. References: [1] Lee SF, Shariati S, Caini S, Wong H, Chan AW, Gojsevic M, et al. StrataXRT for the prevention of acute radiation dermatitis in breast cancer: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 2023;31:515. Keywords: radiation dermatitis, silicone gels, QoL Digital Poster 4822 What are the liver dose constraints during hypofractionated radiotherapy for right breast cancer? Fatma Dhouib, Fatma Missaoui, Leila Farhat, Nejla Fourati, Wicem Siala, Wafa Mnejja, Jamel Daoud oncology radiotherapy, Habib Bourguiba university hospital, SFAX, Tunisia Purpose/Objective: The aim of this study is to evaluate liver doses during hypo fractionated radiotherapy (HFRT) for right-sided breast carcinomas (RSBC) and to assess the need to establish appropriate dose constraints for this regimen. Material/Methods: This retrospective study included the treatment planning data of 40 patients who underwent adjuvant HFRT for RSBC between November 2019 and February 2025. Treatment plans were generated using a three- dimensional conformal radiotherapy technique. The prescribed dose was 42.5 Gy in 16 fractions with a 10 Gy boost in 4 fractions to the tumor bed in cases of breast-conserving surgery (n = 19; 47.5%), and 40 Gy in 15 fractions in cases of mastectomy (n=21; 52.5%). Irradiation of the right axillary area was indicated in 2 patients.The entire liver was retrospectively delineated for all patients. From the dose-volume histogram, we recorded total liver volume, mean (Dmean), maximum (Dmax) and minimum dose (Dmin), and the volumes receiving ≥ 13 Gy, 22 Gy, and 31 Gy (V13, V22, and V31). These dose constraints were calculated using biologically equivalent dose. Data analysis was performed with SPSS version 20. Liver function tests
Digital Poster 4820
Health-related quality-of-life outcomes from a phase II pilot trial of StrataXRT for radiation dermatitis during breast radiotherapy (jRCT1032230451) Mami Ogita, Takuya Hayashi, Masanari Minamitani, Hideomi Yamashita Radiology, The University of Tokyo Hospital, Tokyo, Japan Purpose/Objective: StrataXRT is a silicone-based, film-forming topical gel used to prevent and manage acute radiation dermatitis (ARD)[1]. We conducted a phase II trial to evaluate the efficacy and safety of StrataXRT for ARD during adjuvant breast radiotherapy (RT). In this analysis, we report results for the secondary endpoint, health-related quality of life (HRQoL). Material/Methods: We conducted a single-arm, single-center phase II pilot study. Eligible patients were ≥ 18 years, with histologically confirmed breast cancer, scheduled to receive adjuvant RT. Patients applied StrataXRT from the initiation of RT until two weeks after RT. The primary endpoints —incidence of Grade ≥ 2 ARD and completion of StrataXRT use —have been reported elsewhere. HRQoL was a secondary endpoint. We evaluated HRQoL using the Skin Symptom Assessment (SSA), Radiation-Induced Skin Reaction Assessment Scale (RISRAS), and Skindex-16. We used the Wilcoxon signed-rank test to compare changes from baseline. Results: Between January 2024 and January 2025, 50 patients were enrolled, with a mean age of 53 years. Forty patients had breast-conserving surgery, and 10 had total mastectomy. Ten patients received regional nodal irradiation. Forty patients received moderately hypofractionated radiotherapy (42.56–53.2 Gy in 2.66 Gy/fr), and ten received conventionally fractionated radiotherapy (50–60 Gy in 2.0 Gy/fr). At 14 days post- RT, the patient-reported SSA showed significant increases from baseline in pruritus, blistering or peeling, erythema, and pigmentation (all p < 0.01). At 90 days post-RT, pigmentation and blistering or peeling remained significantly higher than baseline, whereas pain or soreness was significantly lower. On the patient-reported RISRAS, itchiness, burning sensation, impact on daily activities, and the total score were significantly increased at 14 days post-RT (p < 0.01, p = 0.02, p = 0.03, p < 0.01, respectively), while discomfort was significantly decreased at 90 days post-RT compared to baseline. For Skindex-16,
Made with FlippingBook - Share PDF online